Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.1007/s12185-019-02657-3 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Primary Cutaneous Anaplastic Large Cell Lymphoma With Rare Extracutaneous Disseminated Disease: A Case Report.
Am J Dermatopathol
December 2024
Department of Dermatology, Penn State Health Milton S. Hershey Medical Center, Hershey, PA; and.
Primary cutaneous anaplastic large cell lymphoma (pcALCL) is a CD30+ lymphoproliferative disorder with generally favorable outcomes and infrequent extracutaneous spread, usually limited to local lymph nodes. However, there may be extensive histologic overlap with more aggressive CD30+ lymphomas, such as large cell transformation of mycosis fungoides or secondary skin involvement by anaplastic lymphoma kinase (ALK)-negative anaplastic large cell lymphoma. Definitive diagnosis relies on clinicopathologic correlation.
View Article and Find Full Text PDFClinicopathologic features of primary central nervous system anaplastic large cell lymphoma: a multicenter study identifies age and ALK status as prognostic factors.
J Hematop
December 2024
Mayo Clinic, Rochester, MN, USA.
Anaplastic large cell lymphoma with primary presentation in, and disease limited to, the central nervous system (primary CNS ALCL) is a rare and aggressive lymphoma found in a sensitive anatomic site. We report the clinical and pathologic characteristics of 17 primary CNS ALCL cases that are newly reported from six academic medical centers. We are investigating the characteristics of these cases, alongside their commonalities and differences from systemic ALCL arising at conventional anatomic sites.
View Article and Find Full Text PDFAnaplastic Large B-Cell Lymphoma: Cutaneous Presentations.
Cureus
October 2024
Department of Dermatology, Marshall University Joan C. Edwards School of Medicine, Huntington, USA.
Article Synopsis
- Anaplastic large cell lymphoma (ALCL) is a rare T-cell lymphoma marked by the presence of CD30 and can often be mistaken for other conditions due to its vague symptoms.
- A 10-year-old girl initially treated for a bacterial infection was later diagnosed with ALK-negative ALCL after a biopsy revealed the disease, with additional imaging showing lung involvement and a Murphy stage II classification.
- The case highlights the necessity of early biopsy and molecular testing when initial treatments don't work, emphasizing that prompt diagnosis and thorough examinations can significantly enhance treatment success and patient prognosis.
Systemic ALK-negative anaplastic large cell lymphoma with NPM1::TYK2 rearrangement.
J Hematop
December 2024
Department of Pathology, University of Colorado Hospital, University of Colorado School of Medicine, 12605 East 16 Avenue, Aurora, CO, 80045, USA.
Article Synopsis
- Anaplastic large cell lymphoma (ALCL) is a rare type of non-Hodgkin lymphoma, primarily characterized by ALK gene rearrangements, though about 20-50% are ALK negative (ALK- ALCL) and display different genetic changes.
- A unique case of systemic ALK- ALCL involved a genetic fusion (NPM1::TYK2) that complicated diagnosis until next-generation sequencing (NGS) was applied.
- The NGS results revealed clonal rearrangement and a previously unreported NPM1::TYK2 fusion in systemic ALK- ALCL, highlighting its significance and rarity in comparison to other lymphoid conditions.
Real-world effectiveness and safety of recombinant human endostatin plus PD-1 inhibitors and chemotherapy as first-line treatment for EGFR/ALK-negative, advanced or metastatic non-small cell lung cancer.
BMC Cancer
August 2024
Department of Medical Oncology, The Fifth Medical Center of Chinese People's Liberation Army General Hospital, No. 8, Dongda Street, Fengtai District, Beijing, 100071, China.
Background: This study aimed to evaluate the effectiveness and safety of recombinant human endostatin (Rh-endostatin) plus programmed cell death 1 (PD-1) inhibitors and chemotherapy as first-line treatment for advanced or metastatic non-small cell lung cancer (NSCLC) in a real-world setting.
Methods: This was a retrospective study on patients with EGFR/ALK-negative, advanced or metastatic NSCLC. Patients received Rh-endostatin plus PD-1 inhibitors and chemotherapy every three weeks for 4 to 6 cycles.
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!